PYC Therapeutics Secures Approval for Higher Dosage in Phase 1b Multiple Ascending Dose Study in Polycystic Kidney Disease
MT Newswires Live
Jul 29
PYC Therapeutics (ASX:PYC) said it received Safety Review Committee approval in July to escalate dosing in the phase 1b part C multiple ascending dose study in polycystic kidney disease patients to the higher dose group of 2.4 milligrams per kilogram of its drug candidate PYC-003, according to a Wednesday Australian bourse filing.
The company said it also received approval for an open-label extension of the ongoing study to enable continuous dosing of the drug candidate for a period of up to 24 months.
It had AU$669 million of cash on hand as of June 30, per the filing.
PYC Therapeutics' shares rose nearly 2% in recent trading on Wednesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.